BC-3781……A Pleuromutilin by Nabriva (Austria) in phase 2

New Drug Approvals

Antibiotics 02 00500 i025

BC-3781

Topical pleuromutilin antibiotic agent

Gram-positive, including MRSA, PHASE 2 COMPLETED

Nabriva (Austria)

BC-3781
The pleuromutilin BC-3781 belongs to the first generation of pleuromutilins to combine excellent oral
bioavailability with substantial activity against Gram-positive pathogens and atypicals as well as some
Gram-negative pathogens. In particular, BC-3781 is highly active against multi-drug resistant (MDR)
pathogens including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia
(i.e. macrolide and quinolone resistance), and vancomycin resistant Enterococcus faecium. It is
characterized by excellent in vivo activities (e.g. pneumonia model), outstanding PK/PD parameters,
allowing once a day dosing, and a novel mode of action. BC-3781 is being developed for both oral and IV
administration and is intended for the treatment of serious multi-drug resistant skin & skin structure
infections (CSSI) and moderate to severe pneumonia (CAP, HAP etc).

Pleuromutilins have been known since 1951, but only entered the market in 2007 with the approval of retapamulin for…

View original post 709 more words

Cabazitaxel

New Drug Approvals

Cabazitaxel.png

Cabazitaxel

For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotax-11-en-13α-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate

(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-ene-2-yl benzoate

183133-96-2

Jevtana, Taxoid XRP6258, Cabazitaxelum, 183133-96-2, Xrp6258, CHEBI:63584, XRP-6258, TXD 258, XRP 6258
Molecular Formula: C45H57NO14   Molecular Weight: 835.93238

EMA:LinkUS FDA:link

Cabazitaxel is prepared by semi-synthesis from 10-deacetylbaccatin III (10-DAB) which is extracted from yew tree needles. The chemical name of cabazitaxel is (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxy-tax-11-en-2-yl benzoate and is marketed as a 1:1 acetone solvate (propan-2-one),

Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved…

View original post 2,563 more words

NEW DRUG APPROVALS bY DR ANTHONY CRASTO WILL TOUCH 2 LAKH VIEWS THIS MONTH

A highly water-dispersible/magnetically separable palladium catalyst based on a Fe3O4@SiO2 anchored TEG-imidazolium ionic liquid for the Suzuki-Miyaura coupling reaction in water

A highly water-dispersible/magnetically separable palladium catalyst based on a Fe3O4@SiO2 anchored TEG-imidazolium ionic liquid for the Suzuki-Miyaura coupling reaction in water

Green Chem., 2014, Advance Article
DOI: 10.1039/C3GC42311E, Paper
Babak Karimi, Fariborz Mansouri, Hojatollah Vali
*
Corresponding authors
a
Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), P.O. Box 45137-66731, Gava Zang, Zanjan, Iran
b
Anatomy and Cell Biology and Facility for Electron Microscopy Research, McGill University, 3450 University St, Montreal, Canada

A novel ionic liquid functionalized magnetic nanoparticle was prepared by anchoring an imidazolium ionic liquid bearing triethylene glycol moieties on the surface of silica-coated iron oxide nanoparticles.

A novel ionic liquid functionalized magnetic nanoparticle was prepared by anchoring an imidazolium ionic liquid bearing triethylene glycol moieties on the surface of silica-coated iron oxide nanoparticles. The material proved to be an effective host for the immobilization of a Pd catalyst through a subsequent simple ion-exchange process giving a highly water dispersible, active and yet magnetically recoverable Pd catalyst (Mag-IL-Pd) in the Suzuki–Miyaura coupling reaction in water. The as-prepared catalyst displayed remarkable activity toward challenging substrates such as heteroaryl halides and ortho-substituted aryl halides as well as aryl chlorides using very low Pd loading in excellent yields and demonstrating high TONs. Since the catalyst exhibited extremely low solubility in organic solvent, the recovered aqueous phase containing the catalyst can be simply and efficiently used in ten consecutive runs without significant decrease in activity and at the end of the process can be easily separated from the aqueous phase by applying an external magnetic field. This novel double-separation strategywith negligible leaching makes Mag-IL-Pd an eco-friendly and economical catalyst to perform this transformation

CHEMDRAW PRO 8.0

CHEMDRAW PRO 8.0

 

ChemDraw-logoChemDraw is a leading chemistry molecules drawing software. ChemDraw is easy to use and best software for drawing a molecule structures and finding stereochemistry of the molecules.

Features

  • easy to use
  • stereochemistry
  • atom numbers
  • templates each and every type of bond arrows
  • mass fragmentations

and much more….

Screenshot

ChemDraw Pro 8.0

ChemDraw Pro 8.0 provides chemists with a rich set of easy to use tools for creating publication ready, scientifically meaningful drawings of molecules and reactions.

Free download ChemDraw Pro 8.0 full version with product key and serial number from following download link. This download link is test personally and found viruses and spam free.

download button

click link

Specifications

Operating System: Windows 95/NT/98/2000/XP, Windows 7

Size: 47 MB

General procedure of the production of nano and microparticles by the aerosol flow reactor method

The general procedure of the production of nano and microparticles by the aerosol flow reactor method is presented in Figure 1. Materials such as drug, polymer, and/or other excipients are dissolved in a solvent like water and ethanol that are most commonly used solvents. This starting solution is atomized with an appropriate droplet generator. The droplets are carried to a heated tubular laminar flow reactor with the aid of a dry gas or saturated gas. Allowing to use variable flow rates as well as temperatures in the reactor the droplet drying and residence time in the reactor can be fixed. Possible molecular rearrangements such as self-assembling and crystallization occur in this section. Dry aerosols are diluted by large volume of dry gas downstream the reactor to avoid solvent recondensation and wall deposition. Subsequently, the particles are collected by a collector that is suitable for the particular size of the particles.

Particle size and size distribution are determined directly from a gas phase with low-pressure impactors and a differential mobility analyzer (DMA). Particle morphology is observed by a scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Moreover, the crystallinity of the materials can be detected by TEM.

Umirolimus, Biolimus

New Drug Approvals

Biolimus A9.png

Umirolimus, Biolimus

Biosensors (Originator)

40 -O-[(2′-ethoxy) ethyl]rapamycin

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-{(2R)-1-[(1S,3R,4R)-4-(2-Ethoxyethoxy)-3-methoxycyclohexyl]-2-propanyl}-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36 -dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

Umirolimus [INN], Umirolimus [USAN:INN], UNII-U36PGF65JH, TRM-986, 42-O-(2-ethoxyethyl) rapamycin, cas no 851536-75-9
Molecular Formula: C55H87NO14   Molecular Weight: 986.27758
Umirolimus (INN/USAN), is a macrocyclic lactone, a highly lipophilic derivative of sirolimus, an immunosuppressant. This drug is proprietary toBiosensors International, which uses it in its own drug-eluting stents, and licenses it to partners such as Terumo.
Biosensors had been developing a Biolimus A9(R)-eluting coronary stent for the treatment of arterial restenosis. No recent development has been reported. The product candidate was developed with BioMatrix(R), the company’s low-profile, rapid-exchange delivery system. Specifically engineered for use on stents, Biolimus A9(R), a new rapamycin derivative, readily attaches to and enters smooth muscle cell membranes and binds to immunophilins inside the cell, causing cell cycle arrest at G0. Animal and in vitro studies suggest potency and…

View original post 4,351 more words

FRAGRANCE SYNTHESIS…Floralozone and lysmeral

Floralozone

67634-15-5

4-ethyl-a,a-dimethylbenzene propanal; p-ethyl-a,a-dimethylhydrocinnamic aldehyde; a,a-dimethyl-p-ethylphenyl-propanal; 3-(p-ethylphenyl)-2,2-dimethylpropionaldehyde; Florazone; 3-(4-ethylphenyl)-2,2-dimethylpropanal

LYSMERAL

CAS No:80-54-6

CAS Name:Benzenepropanal, 4-(1,1-dimethylethyl)-.alpha.-methyl-

Synonyms p-Tert. Butyl-alpha-methyldihydrocynnamic aldehyde / Lilestralis / Lilial / Lilialdehyde

A current process for producing an aromatic aldehyde compound is shown in Scheme I, wherein production of 4-tert-butyl-phenyl-formaldehyde is critical. The final step of the process requires hydrogen-reduction with palladium on carbon catalyst under high pressure. Use of noble metal as catalyst results in high cost of production. Patent NO. WO2007045641 owned by Badische Anilin- and Soda-Fabrik Corp. (BASF) aims at improving the final step for hydrogen-reduction of the above process. However, the reaction pressure is so high as 30 Bar, leading to difficulties in its industrialization.

Figure US20120264981A1-20121018-C00002

Givaudin Corporation discloses a process for producing an aromatic aldehyde inBull. Soc. Chem. Fr., p 1194 in 1961, as shown in Scheme II. The process utilizes great amounts of TiCland BF3-Et2O as catalyst. However, it has a yield less than 10%. Moreover, one of the raw materials, 2-methylpropenal, is rare and difficult to be obtained, and TiClis easy to be hydrolyzed. Therefore, the process cannot be industrialized and will cause three wastes, that is, waste water, waste gas and industrial residue, leading to environmental pollutions.

Figure US20120264981A1-20121018-C00003

DE2627112 discloses a process for producing an aromatic aldehyde compound as shown in Scheme III. Although its yield is higher than 80%, one of the raw materials, 2-methylpropenal, is extremely rare and high-priced, resulting in the limitation of the process in industrial application. A process published in Journal of Molecular Catalysis A: Chemical, 231(1-2), 61-66 (2005) is a modification of the above process and achieves a theoretical production rate of 95%. However, the modified process requires use of 4-tert-butyliodobenzene as raw material, rare elements as catalyst, and ion liquid for reaction, and has a reaction time more than 24 hours, which leads to its low efficiency and failure in industrial application.

Figure US20120264981A1-20121018-C00004

DE2851024 discloses a process for producing an aromatic aldehyde compound, as shown in Scheme IV. The process requires a great amount of AlCl3, and has problems of three wastes and corrosion of manufacturing equipments. Furthermore, the known Vilsmeier reaction also has problems of three wastes and has a yield of only 35%. A process published in Organic Preparations and Procedures International, 14(1-2), p 2-20 is a modification of the above process. However, the modified process still requires hydrogen-reduction as a final step and utilizes noble metal as catalyst, contributing to its high production cost.

Figure US20120264981A1-20121018-C00005

To overcome the shortcomings, the present invention provides a process for producing an aromatic aldehyde compound that requires no hydrogen-reduction under high pressure with expensive and complicated manufacturing equipments and will not cause pollution to environment to mitigate or obviate the aforementioned problems.

Example-1 Preparation of Compound 1

Compound 1 was obtained by Route 1 and experimental protocols as follows.

Figure US20120264981A1-20121018-C00010

50 grams (0.37 mol) of tert-butylbenzene, 12.3 grams (0.40 mol) of paraformaldehyde and 100 mL of acetic acid were mixed in a flask. 109.6 grams of hydrogen bromide (HBr) in 33% (w/w) acetic acid solution was slowly added into the flask dropwise within 30 minutes and then heated to 120° C. and stirred for 7.5 hours. Samples were obtained and extracted with water and dichloromethane. Organic phase was obtained and subjected to thin-layer chromatography (TLC) for tracing reaction. Until reactants were consumed, 200 mL of water was added into the reaction mixture and then extracted with 200 mL dichloromethane for three times. Organic phases were collected, concentrated and distilled under a condition of a temperature of 165˜170° C. and a pressure of 4.8˜5.5×10−1 torr to obtain distilled fractions. 73.02 grams of compound 1 was obtained with a yield of 86.3%.

Example-2 Preparation of Phase Transfer Catalyst 1 (PTC 1)

Phase transfer catalyst 1 (PTC 1) was obtained by Route 2 and experimental protocols as follows.

Figure US20120264981A1-20121018-C00011

10 grams (220.1 mmol) of compound 1 was dissolved in 200 mL of anhydrous ethanol, followed by adding 14.31 grams (242.1 mmol) of trimethylamine, refluxing for 2 hours and standing overnight. Precipitate was obtained by filtration and rinsed with anhydrous ethanol for three times to obtain a solid, which was dried and ready for use as PTC 1 in the following examples.

Example-3 Preparation of Compound 2

Compound 2 was obtained by Route 3 and experimental protocols as follows.

Figure US20120264981A1-20121018-C00012

50 grams (0.47 mol) of ethylbenzene, 15.56 grams (0.52 mol) of paraformaldehyde and 100 mL acetic acid were mixed in a flask. 138.6 grams of hydrogen bromide in 33% (w/w) acetic acid solution was slowly added into the flask dropwise within 30 minutes and then heated to 120° C. and stirred for 7.5 hours. Samples were obtained and extracted with water and dichloromethane. Organic phase was obtained and subjected to TLC for tracing reaction. When the reaction was finished, 200 mL of water was added and extracted with 200 mL dichloromethane for three times. Organic phases were collected, concentrated and distilled under a condition of a temperature of 151˜156□ and a pressure of 4.2˜4.8×10−1 torr to obtain distilled fractions. 81.66 grams of compound 2 was obtained with a yield of 86.9%.

Example-4 Preparation of Phase Transfer Catalyst 2 (PTC 2)

Phase transfer catalyst 1 (PTC 2) was obtained by Route 4 and experimental protocols as follows.

Figure US20120264981A1-20121018-C00013

10 grams (251.2 mmol) of compound 2 was dissolved in 200 mL of anhydrous ethanol, followed by adding 16.33 grams (276.3 mmol) of trimethylamine, refluxing for 2 hours and standing overnight. Precipitate was obtained by filtration and rinsed with anhydrous ethanol for three times to obtain a solid, which was dried and ready for use as PTC 2 in the following examples.

Comparative Example-1

The present example was performed by the following experimental protocols to produce lysmeral.

2.3 grams (57.7 mmol) of sodium hydroxide, 0.33 grams (0.88 mmol) of tetrabutylammonium iodide, 7.5 mL water, 4.2 mL toluene, 1 mL tetrahydrofuran (THF) were mixed in a flask and then heated to 70˜75° C. Mixture of 10 grams (44.0 mmol) of compound 1 and 3.55 grams (61.2 mmol) of propanal was slowly added into the flask dropwise within 2 hours while the reaction mixture was vigorously stirred. When addition was finished, the reaction mixture was stirred at 70-75° C. for 3 hours and traced by gas chromatography (GC). Until reactants were consumed, 30 mL water was added for extraction to obtain an organic phase. The organic phase was dehydrated with anhydrous sodium sulfate, filtered and concentrated by vacuum distillation. 4.84 grams of lysmeral was obtained with a yield of 53.8%.

Example-5 Preparation of Lysmeral

The present invention was performed according to the following Route 5 and experimental protocols to obtain lysmeral.

Figure US20120264981A1-20121018-C00014

2.3 grams (57.7 mmol) of sodium hydroxide, 0.26 grams (0.88 mmol) of PTC 1, 7.5 mL of water, 4.2 mL of toluene, 1 mL of THF were mixed in a flask and then heated to 70-75° C. Mixture of 10 grams (44.0 mmol) of compound 1 and 3.55 grams (61.2 mmol) of propanal was added into the flask dropwise within 2 hours while the reaction mixture was vigorously stirred. While addition was finished, the reaction mixture was stirred at 70-75° C. for 3 hours and traced by GC. When the reaction stopped, 30 mL water was added for extraction to obtain an organic phase. The organic phase was dehydrated with anhydrous sodium sulfate, filtered and concentrated by vacuum distillation. 7.43 grams of lysmeral was obtained with a yield of 82.6% and verified to have a purity of 97.27% by GC analysis.

Results of analysis by NMR are shown as follows:

1H NMR (CDCl3) □δ 9.73 (t, 1H, J=6.851), 7.34 (ddd, 1H, J=8.032, J=3.716, J=0.000), 7.13 (ddd, 1H, J=8.032, J=3.732, J=0.000), 7.11 (ddd, 1H, J=8.032, J=3.716, J=0.000), 7.32 (ddd, 1H, J=8.032, J=3.732, J=0.000), 2.6 (dd, 2H, J=6.945, J=6.851), 3.0 (tq, 1H, J=6.945, J=6.911), 1.32 (m, 9H), 1.1 (d, 3H, J=6.911).

Results of Comparative Example-1 and Example-5 were shown in Table 1, demonstrating the yields of lysmeral were affected by catalyst and temperature. Table 1 illustrated that reactions with PTC 1 had higher yields than those with tetrabutylammonium iodide.

TABLE 1
reaction temperature phase transfer catalyst yield
20~25° C. tetrabutylammonium iodide no reaction
PTC 1 no reaction
50~60° C. tetrabutylammonium iodide 50.9%
PTC 1 63.1%
70~75° C. tetrabutylammonium iodide 53.8%
PTC 1 82.6%
0.02 equivalent of phase transfer catalyst was used herein.

Comparative Example-2

The present example was performed by the following experimental protocols to produce floralozone.

2.63 grams (65.8 mmol) of sodium hydroxide, 0.37 grams (1.0 mmol) of tetrabutylammonium iodide, 7.5 mL of water, 4.2 mL of toluene, 1 mL of THF were mixed in a flask and then heated to 70˜75° C. Mixture of 10 grams (50.2 mmol) of compound 2 and 5.03 grams (69.8 mmol) of isopropanol was added into the flask dropwise while the reaction mixture was vigorously stirred. When addition was finished, the reaction mixture was stirred at 70-75° C. for 3 hours and traced by GC. When the reaction stopped, 30 mL water was added for extraction to obtain an organic phase. The organic phase was dehydrated with anhydrous sodium sulfate, filtered and concentrated by vacuum distillation. 5.17 grams of floralozone was obtained with a yield of 54.1%.

Example-6 Preparation of Floralozone

The present invention was performed according to the following Route 6 and experimental protocols to obtain floralozone.

Figure US20120264981A1-20121018-C00015

2.63 grams (65.8 mmol) of sodium hydroxide, 0.27 grams (1.0 mmol) of PTC 2, 7.5 mL of water, 4.2 mL of toluene, 1 mL of THF were mixed in a flask and then heated to 70˜75° C. Mixture of 10 grams (50.2 mmol) of compound 2 and 5.03 grams (69.8 mmol) of isopropanal was added into the flask dropwise while the reaction mixture was vigorously stirred. When addition was finished, the reaction mixture was stirred at 70-75° C. for 3 hours and traced by GC. When the reaction stopped, 30 mL of water was added for extraction to obtain an organic phase. The organic phase was dehydrated with anhydrous sodium sulfate, filtered and concentrated by vacuum distillation. 7.92 grams of floralozone was obtained with a yield of 82.8% and verified to have a purity of 95.76% by GC analysis.

Results of analysis by NMR are shown as follows:

1H NMR (CDCl3) □δ 9.62 (m, 1H), 7.15 (ddd, 4H, J=8.026, J=3.500, J=1.319), 2.8 (m, 2H), 2.6 (q, 2H, J=7.486), 1.2 (m, 9H).

Results of Comparative Example-2 and Example-6 were shown in Table 2, demonstrating the yields of floralozone were affected by catalyst and temperature. Table 2 illustrated that reactions with PTC 2 had higher yields than those with tetrabutylammonium iodide.

TABLE 2
reaction temperature phase transfer catalyst yield
20~25° C. tetrabutylammonium iodide no reaction
PTC 2 no reaction
50~60° C. tetrabutylammonium iodide 51.7%
PTC 2 64.6%
70~75° C. tetrabutylammonium iodide 54.1%
PTC 2 82.8%
0.02 equivalent of phase transfer catalyst was used herein.

Here’s a greener process for making fragrance components. Y.-C. Lee and co-inventors improved the process for making aldehydes that are used as fragrances in soaps, detergents, and cosmetics. Compounds specifically covered are floralozone (1) and lysmeral (2).

Current processes for preparing the compounds require a high-pressure hydrogenation step that the inventors believe is unsuitable for industrial use. The new process begins with the preparation of a phase-transfer catalyst (PTC) that is used to make the desired aldehydes.

The first sequence in the figure shows the synthesis of PTC compounds 5a and 5b by the reaction of alkylbenzene 3a or 3b with HCHO and HBr in HOAc. Intermediate 4a is isolated in 86.9% yield after vacuum distillation; it is then treated with NMe3 to produce PTC compound 5a. The PTC is isolated as a solid, but its yield and purity are not reported.

PTC compound 5b is similarly prepared by way of 4b, isolated in 86.3% yield. The PTCs are used to prepare aldehydes 1 and 2.

In the synthesis of 1, shown the second sequence, compound 4a reacts with isobutyraldehyde in a two-phase mixture of water and toluene that contains PTC 5a. Compound 1 is isolated in 82.8% yield with 95.8% purity by GC. A comparative preparation of 1 that uses n-Bu4NI as the catalyst yields only 54.1% product.

The same procedure, shown in the third sequence, is used to produce lysmeral. Bromide6 and propionaldehyde react in the presence of PTC 5b to produce 2 in 82.6% yield and 97.3% purity (GC).

The process uses inexpensive reagents. In contrast to earlier processes, it does not require high pressures or produce hazardous wastes. (UFC Corp. [Taipei]. US Patent 8,362,303, January 29, 2013;